Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778460 | 0.94 | PTGDR2 (0.66) | PTGDR2TDP1TSHRPPARDKDM4E | |
| SCHEMBL3770942 | 0.93 | PTGDR2 (0.74) | PTGDR2TDP1TSHRP2RX3PPARD | |
| SCHEMBL10319365 | 0.92 | PTGDR2 (0.60) | PTGDR2TDP1TSHRPPARDKDM4E | |
| SCHEMBL3772684 | 0.91 | PTGDR2 (0.54) | PTGDR2TDP1TSHRP2RX3KDM4E | |
| SCHEMBL3778555 | 0.91 | PTGDR2 (0.58) | PTGDR2 | |
| SCHEMBL2572400 | 0.91 | PTGDR2 (0.58) | PTGDR2TDP1TSHRKDM4EPKM | |
| SCHEMBL534813 | 0.91 | PTGDR2 (0.58) | PTGDR2TDP1TSHRKDM4EPKM | |
| SCHEMBL20943426 | 0.90 | PTGDR2 (0.54) | PTGDR2TDP1P2RX3KDM4EPKM | |
| SCHEMBL2572457 | 0.90 | PTGDR2 (0.57) | PTGDR2TDP1TSHRPPARDKDM4E | |
| Lysine SCHEMBL19614974 | 0.89 | PTGDR2 (0.56) | PTGDR2TDP1TSHRP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020227570-A1 | METHODS OF TREATING CHRONIC RHINOSINUSITIS WITH PEXOPIPRANT | GB001, INC. (US) | 2020-11-12 | — | — | WO | claimed |
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | claimed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | claimed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | claimed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | claimed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | claimed |
| WO-2020227570-A1 | METHODS OF TREATING CHRONIC RHINOSINUSITIS WITH PEXOPIPRANT | GB001, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227570-A1 | METHODS OF TREATING CHRONIC RHINOSINUSITIS WITH PEXOPIPRANT | GB001, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020227570-A1 | METHODS OF TREATING CHRONIC RHINOSINUSITIS WITH PEXOPIPRANT | GB001, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020172380-A1 | TREATMENT OF ASTHMA PATIENTS HAVING HIGH BASELINE FENO LEVELS | GB001, INC. (US) | 2020-08-27 | — | — | WO | disclosed |
| US-10626089-B2 | Quinoline derivative in crystal form | GBOO1, Inc. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190276405-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | GB005, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3476835-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2019-05-01 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | PTGDR2 146/4885TDP1 4824/4885TSHR 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.